Currenc Group, Inc. (CURR)
USD 1.56
(3.31%)
USD 1.56
(3.31%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 177.67 Million USD | 1177.05% |
| 2022 | 13.91 Million USD | -43.12% |
| 2021 | 24.46 Million USD | -2.46% |
| 2020 | 25.08 Million USD | 32.33% |
| 2019 | 18.95 Million USD | 121.63% |
| 2018 | 8.55 Million USD | 109.13% |
| 2017 | 4.08 Million USD | 265.74% |
| 2016 | 1.11 Million USD | -80.23% |
| 2015 | 5.65 Million USD | 38.11% |
| 2014 | 4.09 Million USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 13.04 Million USD | -92.18% |
| 2024 Q1 | 166.89 Million USD | 1435.87% |
| 2023 FY | 177.67 Million USD | 1177.05% |
| 2023 Q3 | 12.78 Million USD | 10.45% |
| 2023 Q4 | -12.49 Million USD | -197.69% |
| 2023 Q1 | 12.3 Million USD | -11.88% |
| 2023 Q2 | 11.57 Million USD | -5.86% |
| 2022 Q2 | 26.42 Million USD | 4.77% |
| 2022 Q4 | 13.95 Million USD | -7.78% |
| 2022 FY | 13.91 Million USD | -43.12% |
| 2022 Q1 | 25.22 Million USD | 3.12% |
| 2022 Q3 | 15.13 Million USD | -42.73% |
| 2021 Q1 | 24.32 Million USD | -3.03% |
| 2021 FY | 24.46 Million USD | -2.46% |
| 2021 Q4 | 24.46 Million USD | 5.01% |
| 2021 Q3 | 23.29 Million USD | 0.24% |
| 2021 Q2 | 23.23 Million USD | -4.45% |
| 2020 FY | 25.08 Million USD | 32.33% |
| 2020 Q2 | 3.43 Million USD | -75.63% |
| 2020 Q1 | 14.09 Million USD | -25.62% |
| 2020 Q3 | 5.44 Million USD | 58.38% |
| 2020 Q4 | 25.08 Million USD | 360.86% |
| 2019 Q4 | 18.95 Million USD | -8.32% |
| 2019 Q2 | 25.25 Million USD | 362.85% |
| 2019 FY | 18.95 Million USD | 121.63% |
| 2019 Q1 | 5.45 Million USD | -36.19% |
| 2019 Q3 | 20.67 Million USD | -18.14% |
| 2018 Q1 | 5.78 Million USD | 41.58% |
| 2018 FY | 8.55 Million USD | 109.13% |
| 2018 Q4 | 8.55 Million USD | 4.72% |
| 2018 Q3 | 8.16 Million USD | 26.15% |
| 2018 Q2 | 6.47 Million USD | 11.82% |
| 2017 Q4 | 4.08 Million USD | 24.93% |
| 2017 Q3 | 3.27 Million USD | 34.72% |
| 2017 Q2 | 2.42 Million USD | 111.85% |
| 2017 Q1 | 1.14 Million USD | 2.39% |
| 2017 FY | 4.08 Million USD | 265.74% |
| 2016 Q3 | 8352.00 USD | -24.29% |
| 2016 FY | 1.11 Million USD | -80.23% |
| 2016 Q2 | 11.03 Thousand USD | 173.61% |
| 2016 Q1 | 4032.00 USD | 0.0% |
| 2016 Q4 | 1.12 Million USD | 13309.96% |
| 2015 Q4 | 4032.00 USD | -23.67% |
| 2015 FY | 5.65 Million USD | 38.11% |
| 2015 Q3 | 5282.00 USD | 0.0% |
| 2014 FY | 4.09 Million USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Intra-Cellular Therapies, Inc. | 136.87 Million USD | -29.813% |
| PainReform Ltd. | 2.69 Million USD | -6502.591% |
| Alvotech | 1.88 Billion USD | 90.562% |
| Collegium Pharmaceutical, Inc. | 947.87 Million USD | 81.255% |
| ANI Pharmaceuticals, Inc. | 471.67 Million USD | 62.331% |
| Aquestive Therapeutics, Inc. | 163.9 Million USD | -8.402% |
| Journey Medical Corporation | 56.49 Million USD | -214.476% |
| Dynavax Technologies Corporation | 375.02 Million USD | 52.623% |
| Esperion Therapeutics, Inc. | 660.79 Million USD | 73.112% |
| Bright Green Corporation | 6.43 Million USD | -2659.753% |
| Pacira BioSciences, Inc. | 704.25 Million USD | 74.771% |
| Embecta Corp. | 2.03 Billion USD | 91.274% |
| Sunshine Biopharma, Inc. | 6.13 Million USD | -2793.93% |
| Sunshine Biopharma, Inc. | 6.13 Million USD | -2793.93% |
| SCYNEXIS, Inc. | 55.45 Million USD | -220.425% |
| Petros Pharmaceuticals, Inc. | 21.31 Million USD | -733.541% |
| Silver Spike Investment Corp. | 3 Million USD | -5803.18% |
| China SXT Pharmaceuticals, Inc. | 9.19 Million USD | -1831.97% |
| Alpha Teknova, Inc. | 38.55 Million USD | -360.885% |
| Safety Shot Inc | 3.89 Million USD | -4465.101% |
| Procaps Group, S.A. | 462.06 Million USD | 61.547% |
| Cosmos Health Inc. | 30.25 Million USD | -487.309% |
| Theratechnologies Inc. | 98.63 Million USD | -80.127% |
| Harrow Health, Inc. | 241.75 Million USD | 26.505% |
| Sonoma Pharmaceuticals, Inc. | 8.75 Million USD | -1929.188% |
| Biofrontera Inc. | 23.13 Million USD | -667.863% |
| DURECT Corporation | 30.4 Million USD | -484.344% |
| Supernus Pharmaceuticals, Inc. | 487.46 Million USD | 63.551% |
| Cronos Group Inc. | 43.73 Million USD | -306.245% |
| OptiNose, Inc. | 194.33 Million USD | 8.572% |
| Ironwood Pharmaceuticals, Inc. | 817.36 Million USD | 78.262% |
| Kala Pharmaceuticals, Inc. | 48.44 Million USD | -266.758% |
| RedHill Biopharma Ltd. | 20.97 Million USD | -746.957% |
| Organogenesis Holdings Inc. | 181.36 Million USD | 2.033% |
| Guardion Health Sciences, Inc. | 3.77 Million USD | -4610.218% |
| Cumberland Pharmaceuticals Inc. | 52.51 Million USD | -238.326% |
| Radius Health, Inc. | 804.29 Million USD | 77.909% |
| Universe Pharmaceuticals INC | 13.75 Million USD | -1191.78% |
| ProPhase Labs, Inc. | 42.54 Million USD | -317.628% |
| Phibro Animal Health Corporation | 725.54 Million USD | 75.511% |
| Procaps Group S.A. | 462.06 Million USD | 61.547% |
| TherapeuticsMD, Inc. | 14.02 Million USD | -1167.121% |
| Viatris Inc. | 27.21 Billion USD | 99.347% |
| Rockwell Medical, Inc. | 30.88 Million USD | -475.338% |
| Aytu BioPharma, Inc. | 90.37 Million USD | -96.59% |
| SIGA Technologies, Inc. | 57.97 Million USD | -206.457% |
| Tilray Brands, Inc. | 892.11 Million USD | 80.084% |
| Lifecore Biomedical, Inc. | 219.8 Million USD | 19.165% |
| Shineco, Inc. | 47.6 Million USD | -273.255% |
| PetIQ, Inc. | 645.22 Million USD | 72.463% |
| Regencell Bioscience Holdings Limited | 219.51 Thousand USD | -80841.238% |
| Incannex Healthcare Limited | 5.83 Million USD | -2947.611% |
| Neurocrine Biosciences, Inc. | 1.01 Billion USD | 82.571% |
| Alimera Sciences, Inc. | 107.35 Million USD | -65.505% |
| Assertio Holdings, Inc. | 148.41 Million USD | -19.715% |
| Shuttle Pharmaceuticals Holdings, Inc. | 1.89 Million USD | -9271.256% |
| Clever Leaves Holdings Inc. | 7.02 Million USD | -2428.832% |
| Cyclo Therapeutics, Inc. | 8.49 Million USD | -1992.634% |
| Avadel Pharmaceuticals plc | 173.38 Million USD | -2.474% |
| Hempacco Co., Inc. | 18.82 Million USD | -843.959% |
| Talphera, Inc. | 6.29 Million USD | -2724.733% |
| Alvotech | 1.88 Billion USD | 90.562% |
| Eagle Pharmaceuticals, Inc. | 172.6 Million USD | -2.941% |
| Lantheus Holdings, Inc. | 835.25 Million USD | 78.728% |
| Kamada Ltd. | 109.96 Million USD | -61.57% |
| Indivior PLC | 1.95 Billion USD | 90.894% |
| Evoke Pharma, Inc. | 9.64 Million USD | -1741.565% |
| Flora Growth Corp. | 17.22 Million USD | -931.679% |
| Cyclo Therapeutics, Inc. | 8.49 Million USD | -1992.634% |
| Evolus, Inc. | 209.68 Million USD | 15.266% |
| HUTCHMED (China) Limited | 536.38 Million USD | 66.875% |
| Amphastar Pharmaceuticals, Inc. | 873.49 Million USD | 79.659% |
| Akanda Corp. | 12.66 Million USD | -1302.458% |